Instead of building generic chatbot wrappers, entrepreneurs should target high-value niches by building tools on top of specialized AI models. For example, creating an 'AlphaFold wrapper' could create a multi-billion dollar company by serving the specific workflow needs of pharmaceutical companies and research labs.

Tools are emerging that don't just build an app but run the entire company—managing marketing, bookkeeping, and legal. This evolution shows the value is not in the LLM itself but in the 'harness' built around it to orchestrate complex business functions, creating a new category of fully autonomous company builders.

Contrary to expectations that the first billion-dollar one-person company would be an AI developer, Medvy's founder achieved this scale by using AI to turbocharge a traditional business model—acting as a middleman for weight loss drugs.

Most successful SaaS companies weren't built on new core tech, but by packaging existing tech (like databases or CRMs) into solutions for specific industries. AI is no different. The opportunity lies in unbundling a general tool like ChatGPT and rebundling its capabilities into vertical-specific products.

OpenAI's launch of ChatGPT Health, which integrates medical records, signals a clear strategy to move beyond general-purpose APIs. Foundation model companies are now building specialized, vertical-specific products, posing a direct threat to "wrapper" startups that rely on the underlying models' existing capabilities.

Successful vertical AI applications serve as a critical intermediary between powerful foundation models and specific industries like healthcare or legal. Their core value lies in being a "translation and transformation layer," adapting generic AI capabilities to solve nuanced, industry-specific problems for large enterprises.

The founder of Medvy built a massive telehealth business by using a "telehealth in a box" platform for doctors, pharmacies, and compliance. This allowed him to focus exclusively on AI-driven branding and marketing to acquire customers at scale.

While AI-driven drug discovery is the ultimate goal, Titus argues its most practical value is in improving business efficiency. This includes automating tasks like literature reviews, paper drafting, and procurement, freeing up scientists' time for high-value work like experimental design and interpretation.

The common analogy of AI being "like a website" that every company must adopt may be misleading. The real transformative power of AI could be in enabling entirely new, AI-native businesses that leapfrog incumbents, rather than simply being a feature tacked onto existing products.